Zhenwei Peng

List of Publications by Year
in descending order

54 papers	1,255 citations	471509 17 h-index	395702 33 g-index
56 all docs	56 docs citations	56 times ranked	1497 citing authors

#	Article	IF	Citations
1	Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI. European Radiology, 2019, 29, 4648-4659.	4.5	144
2	Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget, 2016, 7, 17220-17229.	1.8	113
3	Tumor-on-a-chip: from bioinspired design to biomedical application. Microsystems and Nanoengineering, 2021, 7, 50.	7.0	103
4	The Effects of Anesthetic Technique on Cancer Recurrence in Percutaneous Radiofrequency Ablation of Small Hepatocellular Carcinoma. Anesthesia and Analgesia, 2012, 114, 290-296.	2.2	82
5	Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6â€Methyladenosine mRNA Methylationâ€Dependent Mechanism. Hepatology, 2021, 74, 1339-1356.	7.3	62
6	Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. Radiology, 2018, 287, 705-714.	7.3	59
7	Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation. Oncogene, 2018, 37, 3514-3527.	5.9	57
8	Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma. Radiology, 2019, 292, 237-247.	7.3	53
9	Sublethal heat treatment of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent manner. Cancer Letters, 2019, 460, 29-40.	7.2	48
10	Nearâ€Infrared II Lightâ€Triggered Robust Carbon Radical Generation for Combined Photothermal and Thermodynamic Therapy of Hypoxic Tumors. Advanced Functional Materials, 2021, 31, 2101709.	14.9	42
11	Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study. European Radiology, 2018, 28, 3522-3531.	4.5	40
12	Irreversible electroporation induces CD8+ T cell immune response against post-ablation hepatocellular carcinoma growth. Cancer Letters, 2021, 503, 1-10.	7.2	40
13	Safety margin after radiofrequency ablation of hepatocellular carcinoma: precise assessment with a three-dimensional reconstruction technique using CT imaging. International Journal of Hyperthermia, 2018, 34, 1135-1141.	2.5	38
14	Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 454.	8.6	38
15	Autocrine STIP1 signaling promotes tumor growth and is associated with disease outcome in hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2017, 493, 365-372.	2.1	31
16	Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma. Cancer Immunology Research, 2022, 10, 728-744.	3.4	27
17	Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?. Radiology, 2021, 298, 680-692.	7.3	23
18	Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e2126992.	5.9	20

#	Article	IF	Citations
19	TRPM7 Regulates AKT/FOXO1â€“Dependent Tumor Growth and Is an Independent Prognostic Indicator in Renal Cell Carcinoma. Molecular Cancer Research, 2018, 16, 1013-1023.	3.4	19
20	Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. JAMA Network Open, 2018, 1, e183213.	5.9	19
21	FSCN1 predicts survival and is regulated by a PI3Kâ€dependent mechanism in renal cell carcinoma. Journal of Cellular Physiology, 2018, 233, 4748-4758.	4.1	18
22	Nanomedicine promotes ferroptosis to inhibit tumour proliferation in vivo. Redox Biology, 2021, 42, 101908.	9.0	18
23	Combined radiofrequency ablation and ethanol injection versus repeat hepatectomy for elderly patients with recurrent hepatocellular carcinoma after initial hepatic surgery. International Journal of Hyperthermia, 2018, 34, 1029-1037.	2.5	17
24	Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: A phase 3, multicenter, randomized controlled trial.. Journal of Clinical Oncology, 2022, 40, 380-380.	1.6	17
25	Percutaneous microwave ablation of 5-6â€‰cm unresectable hepatocellular carcinoma: local efficacy and long-term outcomes. International Journal of Hyperthermia, 2017, 33, 247-254.	2.5	16
26	Combined percutaneous radiofrequency ablation and ethanol injection versus hepatic resection for 2.1â€“5.0 cm solitary hepatocellular carcinoma: a retrospective comparative multicentre study. European Radiology, 2018, 28, 3651-3660.	4.5	15
27	Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma. Journal of Oncology, 2019, 2019, 1-7.	1.3	15
28	Liver resection versus transarterial chemoembolization for the treatment of intermediateâ€stage hepatocellular carcinoma. Cancer Medicine, 2019, 8, 1530-1539.	2.8	14
29	NO-dependent vasodilation and deep tumor penetration for cascade-amplified antitumor performance. Journal of Controlled Release, 2022, 347, 389-399.	9.9	14
30	Development and Validation of a Risk Score for Prediction of Venous Thromboembolism in Patients With Lung Cancer. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962091079.	1.7	11
31	Microvascular Invasion Status and Its Survival Impact in Hepatocellular Carcinoma Depend on Tissue Sampling Protocol. Annals of Surgical Oncology, 2021, 28, 6747-6757.	1.5	11
32	Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model. BMC Cancer, 2018, 18, 1108.	2.6	6
33	The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model. Quality of Life Research, 2020, 29, 629-638.	3.1	6
34	Can Epsteinâ€“Barr virusâ€deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?. Cancer Medicine, 2023, 12, 223-235.	2.8	3
35	Prognostic Role of Time to Surgery in Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer Stage 0-A. Annals of Surgical Oncology, 2020, 27, 3740-3753.	1.5	2
36	Association of Virological Response to Antiviral Therapy With Survival in Intermediate-Stage Hepatitis B Virus-Related Hepatocellular Carcinoma After Chemoembolization. Frontiers in Oncology, 2021, 11, 751777.	2.8	2

#	Article	IF	Citations
37	The combination of radiotherapy and immunotherapy is effective and well tolerated for unresectable biliary tract cancer. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.8	2
38	Role of Preoperational Imaging Traits for Guiding Treatment in Single â‰Â5Âcm Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	2
39	The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion. International Journal of Hyperthermia, 2022, 39, 688-696.	2.5	2
40	IDDF2019-ABS-0095â€...Can artificial intelligence support the clinical decision making for hepatocellular carcinoma?. , 2019, , .		1
41	Survival Benefits of Anti-PD-1 Therapy in Combination With Radiotherapy in Chinese Melanoma Patients With Brain Metastasis. Frontiers in Oncology, 2021, 11, 646328.	2.8	1
42	Radiofrequency ablation plus nucleotide analogous for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis. American Journal of Translational Research (discontinued), 2018, 10, 2685-2695.	0.0	1
43	IDDF2019-ABS-0082â€...Microvascular invasion at primary resection guiding the therapeutic options of recurrent intermediate-advanced hepatocellular carcinoma. , 2019, , .		0
44	IDDF2019-ABS-0215â€...Antimicrobial prophylaxis after hepatic resection for hepatocellular carcinoma: a propensity score matching study. , 2019, , .		0
45	IDDF2019-ABS-0273â€...Hepatic resection versus transcatheter arterial chemoembolization in resectable infiltrative hepatocellular carcinoma: a propensity score weighted landmark study. , 2019, , .		0
46	IDDF2019-ABS-0079â€...Impact of time-to-surgery on the prognosis of hepatocellular carcinoma patients at bclc stage 0-a after liver resection. , 2019, , .		0
47	IDDF2019-ABS-0078â€...A pre-operative prognosis score for advanced hepatocellular carcinoma (hcc) patients underwent resection. , 2019, , .		0
48	IDDF2019-ABS-0094â€...Tumor size and location affecting the treatment selection for solitary small recurrent hepatocellular carcinoma (â‰3.0 cm) after initial hepatectomy. , 2019, , .		0
49	Tumor size and location affecting the treatment selection for solitary small recurrent hepatocellular carcinoma (â‰3.0 cm) after initial hepatectomy.. Journal of Clinical Oncology, 2019, 37, e15660-e15660.	1.6	0
50	Microvascular invasion guiding selection of candidates for combination treatment with sorafenib and TACE for intermediate recurrent hepatocellular carcinoma.. Journal of Global Oncology, 2019, 5, 105-105.	0.5	0
51	Tumor size and location affecting the treatment selection for solitary small recurrent hepatocellular carcinoma (â‰3.0cm) after initial hepatectomy.. Journal of Global Oncology, 2019, 5, 106-106.	0.5	0
52	IDDF2020-ABS-0065â€...Safety and efficacy of laparoscopic microwave ablation and portal vein ligation for staged hepatectomy (LAPS) in patients with hbv-related hepatocellular carcinoma. , 2020, , .		0
53	Cost-Effectiveness Analysis of Follow-Up Schedule for Hepatocellular Carcinoma after Radiofrequency Ablation. Journal of Oncology, 2022, 2022, 1-9.	1.3	0
54	ASO Author Reflections: Intertumor Biological Heterogeneity Counts in Treatment Selection of Single â‰ 5 cm Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	0